Leveraging AbClick 바카라사이트 신고 platform with anticipated synergies with CDMO companies in the 바카라사이트 신고 sector
[by Lee, Young Sung] AbTis, a company specializing in ADC therapeutics development, announced on May 13 that it has signed a Toolbox partnership business agreement (MOU) with ChemExpress, a Shanghai-based ADC contract development and manufacturing organization (CDMO).
The Toolbox partnership is an integrated platform that seamlessly combines different technologies and solutions, allowing customers to select and utilize services tailored to their specific needs.
바카라사이트 신고 aims to enhance the safety and efficacy of ADCs compared to existing technologies through its proprietary location-selective antibody conjugation platform, 'AbClick®’. ChemExpress, a specialized CDMO in the ADC sector, offers a comprehensive one-stop platform capable of supporting the entire process from research and development to GMP production.
Through this agreement, 바카라사이트 신고 and ChemExpress will integrate their respective ADC research and development capabilities, leveraging their combined global networks to attract new customers, expand into new markets, and deliver innovative and efficient solutions to customers.
In particular, the two companies plan to extend their collaboration beyond the AppClick platform, integrating their core strengths in antibody conjugation technology and industrialization to jointly advance the development of next-generation 바카라사이트 신고s.
Through this collaboration, the companies aim to enhance the competitiveness of the global 바카라사이트 신고 industry and generate sustainable value for human health by providing innovative therapies to patients more rapidly.
“ChemExpress is one of the pioneering companies in ADC research in China, with strong technological capabilities and a highly skilled talent pool,” expressed Han Tae-dong, CEO of 바카라사이트 신고. “By integrating the AbClick technology platform and ChemExpress’ strengths, we aim to further expand the application of position-selective antibody conjugation technology, ultimately contributing to the delivery of safer and more effective precision treatments for patients.”
“We are very pleased to enter into this strategic agreement with 바카라사이트 신고, which possesses the third-generation antibody conjugation technology platform AbClick,” stated Zheng Baofu, Chairman of ChemExpress. “Through this collaboration, we aim to maximize the combined strengths of both companies, accelerating the development of ADC and bioconjugate novel drugs and providing benefits to patients worldwide more rapidly,” he added.